The Bethesda System for cervical cytology

Gynaecology

Also known as: Bethesda-System (Zervixzytologie) · Bethesda sistemi (serviks sitolojisi) · Bethesda System (cervical cytology)

What it is for

The Bethesda System (TBS) 2014 for reporting cervical cytology, used in the USA and internationally.

Category	Description
Specimen adequacy	satisfactory or unsatisfactory for evaluation.
Negative for intraepithelial lesion or malignancy (NILM)	no epithelial abnormality (organisms and reactive changes may be reported).
Squamous cell abnormalities, in order	atypical squamous cells of undetermined significance (ASC-US); atypical squamous cells, cannot exclude HSIL (ASC-H); low-grade squamous intraepithelial lesion (LSIL: HPV cytopathic effect, mild dysplasia, CIN 1); high-grade squamous intraepithelial lesion (HSIL: moderate and severe dysplasia, carcinoma in situ, CIN 2 and CIN 3), qualified as 'with features suspicious for invasion' (if invasion is suspected); squamous cell carcinoma.
Glandular cell abnormalities	atypical glandular cells (AGC: endocervical, endometrial or glandular cells, not otherwise specified or specified in comments); atypical cells, favour neoplastic (endocervical or glandular); endocervical adenocarcinoma in situ (AIS); adenocarcinoma (endocervical, endometrial, extrauterine, not otherwise specified).
Other malignant neoplasms	reported with the type specified.
Other	endometrial cells in a woman aged 45 years or older (TBS 2001 used 40 years); the report states whether a squamous intraepithelial lesion is absent.